Back to top
more

DURECT (DRRX)

(Delayed Data from NSDQ)

$0.91 USD

0.91
115,709

+0.03 (3.64%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $0.91 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for DRRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

DURECT Corporation [DRRX]

Reports for Purchase

Showing records 1 - 20 ( 140 total )

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 1

03/05/2024

Daily Note

Pages: 3

Charles River to Help Market ALZET; EOP2 Meeting in 1Q24 to Determine Larsucosterol''s Path Forward; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 2

11/14/2023

Company Report

Pages: 6

3Q Recap: We Look For EOP2 Meeting With The FDA in 1Q24 to Determine Larsucosterol''s Future; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 3

11/08/2023

Company Report

Pages: 5

Phase 2b AHFIRM in Severe AH Is a Flop, Missing Primary and Secondary Endpoints; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 4

09/07/2023

Daily Note

Pages: 3

Last Patient''s Last Visit Completed in AHFIRM Phase 2b AH Trial; 4Q23 Top-Line Data In-Line With Guidance; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 5

08/10/2023

Company Report

Pages: 7

2Q Recap: With LPLV in Early September, We Await AHFIRM Topline Data in 4Q23; Affirm Buy, Trim PT to $27

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 6

06/07/2023

Daily Note

Pages: 4

Countdown to Potentially Transformational Catalyst: Phase 2b AHFIRM Study Completes Enrollment; Top-line Data in 4Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 7

05/09/2023

Company Report

Pages: 7

1Q Recap: AHFIRM on the Cusp of Full Enrollment; Potential Registrational Data Readout in 2H23; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 8

04/11/2023

Daily Note

Pages: 5

Study Cross Comparisons Highlight Larsucosterol''s Efficacy in AH Over SoC

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 9

03/08/2023

Company Report

Pages: 7

4Q Recap; AHFIRM Complete Enrollment Expected 2Q23; Positive Data Could Lead to $3B+ Opportunity; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 10

12/06/2022

Company Report

Pages: 8

1-for-10 Reverse Stock Split Becomes Effective; Adjusting PT to $35 on Model Updates; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 11

11/03/2022

Company Report

Pages: 7

3Q Recap; AHFIRM Pace of Enrollment Faster Than Expected; Complete Enrollment Now Expected in 2Q23; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 12

09/27/2022

Daily Note

Pages: 3

Innocoll Launches POSIMIR in the U.S., Triggering $2M Milestone Payment to DURECT; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 13

08/05/2022

Company Report

Pages: 7

2Q Recap; We Expect AHFIRM''s Modified Endpoint to Reflect Larsucosterol''s Expanded Benefit in AH; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 14

05/05/2022

Company Report

Pages: 6

1Q Recap; AHFIRM Pace of Enrollment Begins to Accelerate; Last Patient Dosing Expected in Mid-2023; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 15

04/18/2022

Company Report

Pages: 8

With AHFIRM''s Complete Enrollment Expected in Mid-2023, DURECT Works to Expand Awareness For AH

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 16

03/08/2022

Company Report

Pages: 6

4Q Recap; DURECT Expects New AHFIRM Sites to Support Complete Enrollment in Mid-2023; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 17

03/04/2022

Daily Note

Pages: 3

CFO Departure Has No Impact on Our Positive Thesis; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 18

03/02/2022

Daily Note

Pages: 3

First European Patient Dosed in Lead Phase 2b Study in Severe Alcoholic Hepatitis; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 19

12/23/2021

Daily Note

Pages: 3

We See Clear Synergies in Licensing POSIMIR to Innocoll in Order to Maximize its Sales Potential; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 20

11/12/2021

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party